These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35462108)

  • 41. Reply to: The 4-Copy Conundrum in the Treatment of Infants with Spinal Muscular Atrophy.
    Yeo CJJ; Simmons Z; De Vivo DC; Darras BT
    Ann Neurol; 2022 Jun; 91(6):892. PubMed ID: 35332578
    [No Abstract]   [Full Text] [Related]  

  • 42. Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1.
    Bruno G; Donnarumma B; Inverardi A; Buonpensiero P; Sepe A; Tosco A; Raia V; Varone A
    Pediatr Pulmonol; 2021 Jun; 56(6):1806-1808. PubMed ID: 33684256
    [No Abstract]   [Full Text] [Related]  

  • 43. Single-Dose Intrathecal Dorsal Root Ganglia Toxicity of Onasemnogene Abeparvovec in Cynomolgus Monkeys.
    Tukov FF; Mansfield K; Milton M; Meseck E; Penraat K; Chand D; Hartmann A
    Hum Gene Ther; 2022 Jul; 33(13-14):740-756. PubMed ID: 35331006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In brief: Risdiplam (Evrysdi) for spinal muscular atrophy.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e1-e2. PubMed ID: 34544108
    [No Abstract]   [Full Text] [Related]  

  • 45. Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy.
    Lee S; Lee YJ; Kong J; Ryu HW; Shim YK; Han JY; Woo H; Kim SY; Cho A; Lim BC; Chae JH
    Brain Dev; 2022 Apr; 44(4):287-293. PubMed ID: 35033405
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Onasemnogene Abeparvovec: First Global Approval.
    Hoy SM
    Drugs; 2019 Jul; 79(11):1255-1262. PubMed ID: 31270752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Child Neurology: Pathologically Confirmed Thrombotic Microangiopathy Caused by Onasemnogene Abeparvovec Treatment for SMA.
    Yazaki K; Sakuma S; Hikita N; Fujimaru R; Hamazaki T
    Neurology; 2022 May; 98(19):808-813. PubMed ID: 35351784
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Guidance on Gene Replacement Therapy in Spinal Muscular Atrophy: A Canadian Perspective.
    Oskoui M; Gonorazky H; McMillan HJ; Dowling JJ; Amin R; Gagnon C; Selby K
    Can J Neurol Sci; 2022 May; 49(3):398-401. PubMed ID: 34082851
    [No Abstract]   [Full Text] [Related]  

  • 49. Adeno-associated virus serotype 9 antibody titers in patients with SMA pre-screened for treatment with onasemnogene abeparvovec -routine care evidence.
    Aharoni S; Bistritzer J; Levine H; Sagi L; Fattal-Valevski A; Ginzberg M; Noyman I; Cohen R; Nevo Y
    Gene Ther; 2023 Feb; 30(1-2):101-106. PubMed ID: 35474244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs.
    Ballreich J; Ezebilo I; Khalifa BA; Choe J; Anderson G
    J Manag Care Spec Pharm; 2022 Jan; 28(1):39-47. PubMed ID: 34949120
    [No Abstract]   [Full Text] [Related]  

  • 51. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
    Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
    Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec.
    Day JW; Finkel RS; Mercuri E; Swoboda KJ; Menier M; van Olden R; Tauscher-Wisniewski S; Mendell JR
    Mol Ther Methods Clin Dev; 2021 Jun; 21():76-82. PubMed ID: 33768131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in the Therapy of Spinal Muscular Atrophy.
    Klotz J; Tesi Rocha C; Dunaway Young S; Duong T; Buu M; Sampson J; Day JW
    J Pediatr; 2021 Sep; 236():13-20.e1. PubMed ID: 34197889
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular Atrophy.
    Matesanz SE; Battista V; Flickinger J; Jones JN; Kichula EA
    Pediatr Neurol; 2021 May; 118():1-5. PubMed ID: 33677142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Access to orphan drugs for the treatment of spinal muscular atrophy in Spain].
    García-Parra B; Guiu JM; Modamio P; Martínez-Yélamos A; Mariño-Hernández EL; Povedano M
    Rev Neurol; 2022 Nov; 75(9):261-267. PubMed ID: 36285446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
    Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
    Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medical therapy in spinal muscular atrophy: a realistic expectation?
    Jennekens FG
    Clin Neurol Neurosurg; 1992; 94 Suppl():S89-92. PubMed ID: 1320532
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I.
    Mirea A; Shelby ES; Axente M; Badina M; Padure L; Leanca M; Dima V; Sporea C
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy.
    Kirschner J; Butoianu N; Goemans N; Haberlova J; Kostera-Pruszczyk A; Mercuri E; van der Pol WL; Quijano-Roy S; Sejersen T; Tizzano EF; Ziegler A; Servais L; Muntoni F
    Eur J Paediatr Neurol; 2020 Sep; 28():38-43. PubMed ID: 32763124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
    Day JW; Mendell JR; Mercuri E; Finkel RS; Strauss KA; Kleyn A; Tauscher-Wisniewski S; Tukov FF; Reyna SP; Chand DH
    Drug Saf; 2021 Oct; 44(10):1109-1119. PubMed ID: 34383289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.